Metachromatic Leukodystrophy - Competitive Landscape and Market Insights, 2018

October 2018 | 58 pages | ID: M5DC77BCF97EN
DelveInsight

Abstracts

This report can be delivered to the clients within 48 hours

'Metachromatic Leukodystrophy - Competitive Landscape and Market Insights, 2018', report provides comprehensive insights about pipeline drugs along with technologies involved across this indication. The report provides the detailed analysis of pipeline products along with the companies involved. The report covers the Market Scenario till 2027, Attribute analysis, Product Potential Analysis, Metachromatic Leukodystrophy Market Evolution, and Unmet Needs. This report further provides comprehensive insights about the pipeline drugs. It covers all the clinical pipeline drug profiles and their comparative analysis along with forecasted sales for upcoming launches.

Products covered by Phase

• Phase III and Phase II
• Pre-clinical and Discovery

Overview of pipeline development activities for Metachromatic Leukodystrophy

Pipeline analysis of the therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and non-clinical results, designations, collaborations & licensing deals, grants, technology and patent details.

METHODOLOGY

Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.

Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

SCOPE

• The report provides competitive pipeline landscape of Metachromatic Leukodystrophy
• The report provides the insight of current and future market for Metachromatic Leukodystrophy
• The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
• Coverage of the Metachromatic Leukodystrophy pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
• The report reviews key players involved in the therapeutics development for Metachromatic Leukodystrophy and also provide company profiling
• Pipeline products coverage based on various stages of development ranging from late stage till discovery stage
• Provides attribute analysis Report also covers the Attribute analysis, Product Potential Analysis, Metachromatic Leukodystrophy Market Evolution, Market Scenario, and Unmet Needs

REASONS TO BUY

• Identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage
• Establish a comprehensive understanding of the current pipeline scenario across Metachromatic Leukodystrophy to formulate effective R&D strategies
• Assess challenges and opportunities that influence Metachromatic Leukodystrophy R&D
• Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
• Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
• Devise corrective measures for pipeline projects by understanding Metachromatic Leukodystrophy pipeline depth and focus of indication therapeutics
• Developing strategic initiatives to support your drug development activities
• Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Metachromatic Leukodystrophy to enhance and expand business potential and scope
• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Gaining a full picture of the Competitive Landscape for Evidence based Decisions

Contents

Overview
Metachromatic Leukodystrophy (MLD)
Causes
Pathophysiology
Types
Symptoms
Diagnosis
Treatment and Management
Epidemiology- 7MM
Key Findings

7MM

Assumptions and Rationale
Incidence of MLD in 7MM
Prevalence of MLD in 7MM
Competitive Landscape
Pipeline Scenario
GSK-2696274: GlaxoSmithKline
Product Description
Research and Development
Product Development Activities
GSK-2696274: Forecasted Sales
GSK-2696274: Analyst’s Insights
(The list continues)
Institutional Research
DUOC-01: Duke University Medical Center
Product Description
Research and Development
DUOC-01: Analyst’s Insights
(The list continues)
Market Assessment

7MM MARKET SIZE

Market Evolution
Attribute Analysis
Product Potential Analysis
Unmet Needs

List Of Tables

LIST OF TABLES

Table 1: 7MM, MLD Incident Cases, 2015-2027
Table 2: 7MM, MLD Prevalent Cases, 2015-2027
Table 3: 7MM Market Size (in USD million)

List Of Figures

LIST OF FIGURES

Figure 1: Effects of MLD
Figure 2: Types of MLD
Figure 3: Symptoms of MLD
Figure 4: 7MM, MLD Incident Cases, 2015-2027
Figure 5: 7MM, MLD Prevalent Cases, 2015-2027
Figure 6: GSK-2696274, Forecasted Sales
Figure 7: SHP611, Forecasted Sales
Figure 8: 7MM Overall Market Size